Human studies of the long-acting form
Teichman and colleagues' hormone study, published in 2006, followed healthy adults. It supports the half-life estimate and the finding that growth hormone and IGF-1, a related growth factor, stayed elevated for days. It didn't measure better sleep or recovery.
Ionescu and Frohman's pulse study, also published in 2006, examined growth hormone's rising-and-falling pattern. Those pulses continued while hormone levels increased. That result doesn't establish long-term safety.
Preparation names and evidence limits
Jette and colleagues' albumin-binding research, published in 2005, explored the long-acting design in laboratory and animal work. Albumin is a protein in blood; attaching to it helps explain the prolonged activity.
FDA's December 2024 meeting document examines the related preparations, confusing names, human evidence and safety concerns. It found no human studies of the no-DAC forms and no effectiveness studies in people with growth hormone deficiency.
Safety, status and missing results
FDA's bulk-substance safety page, current as of April 22, 2026, lists CJC-1295 as nominated but withdrawn. Safety concerns remain beside the entry. That page date isn't an individual withdrawal date, and withdrawal isn't clearance for compounding.
The clinical trial record concerns people with HIV and excess abdominal fat. It lists the study as terminated, with no results posted. I don't turn a planned study into a finding.
FDA's explanation of compounded-drug risks provides general background. Compounded medicines aren't FDA-approved; FDA doesn't review their safety, effectiveness or quality before marketing.
FDA's ingredient rules for ordinary pharmacy compounding explain the three routes a raw ingredient can meet: an applicable official quality standard, being part of an approved drug or appearing on the 503A bulks list in federal regulations. CJC-1295 isn't on that list. A prescription doesn't replace the ingredient rules.